Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies

Juanjuan Shang,Shunfeng Hu,Xin Wang

DOI: https://doi.org/10.1186/s40164-024-00481-y

2024-02-26

Experimental Hematology and Oncology

Abstract:Natural killer (NK) cell belongs to innate lymphoid cell family that contributes to host immunosurveillance and defense without pre-immunization. Emerging studies have sought to understand the underlying mechanism behind NK cell dysfunction in tumor environments, and provide numerous novel therapeutic targets for tumor treatment. Strategies to enhance functional activities of NK cell have exhibited promising efficacy and favorable tolerance in clinical treatment of tumor patients, such as immune checkpoint blockade (ICB), chimeric antigen receptor NK (CAR-NK) cell, and bi/trispecific killer cell engager (BiKE/TriKE). Immunotherapy targeting NK cell provides remarkable advantages compared to T cell therapy, including a decreased rate of graft versus-host disease (GvHD) and neurotoxicity. Nevertheless, advanced details on how to support the maintenance and function of NK cell to obtain better response rate and longer duration still remain to be elucidated. This review systematically summarizes the profound role of NK cells in tumor development, highlights up-to-date advances and current challenges of therapy targeting NK cell in the clinical treatment of hematologic malignancies.

oncology,hematology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the dysfunction of natural killer cells (NK cells) in hematological malignancies and its impact on clinical treatment. Specifically, the paper focuses on the following aspects:

1. **Dysfunction of NK cells**: The paper analyzes in detail the mechanism of the decline in NK cell function in the tumor microenvironment, including how factors such as abnormal surface receptors, disruption of killing pathways, and metabolic changes affect the activity and function of NK cells.

2. **Metabolic changes of NK cells in the tumor microenvironment**: It studies how metabolic changes such as glucose deficiency, lipid accumulation, amino acid starvation, and the cytotoxicity of reactive oxygen species (ROS) inhibit the function of NK cells.

3. **Immunosuppressive factors**: It discusses how hypoxia, abnormal chemokine environment, and immunosuppressive factors secreted by tumors lead to NK cell dysfunction.

4. **Immunotherapy targeting NK cells**: It reviews current immunotherapy methods targeting NK cells, such as CAR - NK cells, bispecific/trispecific killer cell engagers (BiKE/TriKE), immune checkpoint blockade (ICB), etc., as well as the applications and challenges of these methods in the treatment of hematological malignancies.

Through these analyses, the paper aims to provide new strategies and ideas for the immunotherapy of hematological malignancies, especially in terms of improving the function and persistence of NK cells.